With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.871022-62-7,tert-Butyl ((4-fluoropiperidin-4-yl)methyl)carbamate,as a common compound, the synthetic route is as follows.
[00344] Step a: A mixture of 3-((3-amino-2-chlorophenyl)thio)-6-chloropyrazin-2- amine (200 mg, 0.696 mmol) and tert-butyl ((4-fluoropiperidin-4-yl)methyl)carbamate (243 mg, 1.045 mmol), and DIPEA (0.6 mL, 3.48 mmol) in NMP (2 mL) was stirred for 16 h at 150 C. After cooling to RT, the reaction mixture was poured into a separation funnel containing brine and it was extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over MgS04, filtered and the volatiles were removed under reduced pressure. The resulting residue was purified by silica chromatography (0 to 10% gradient of MeOH DCM) to give tert-butyl ((l-(6-amino-5- ((3-amino-2-chlorophenyl)thio)pyrazin-2-yl)-4-fluoropiperidin-4-yl)methyl)carbamate (285 mg, 0.590 mmol). MS m/z 483.1 (M+H)+.
871022-62-7, As the paragraph descriping shows that 871022-62-7 is playing an increasingly important role.
Reference£º
Patent; NOVARTIS AG; CHEN, Zhuoliang; DORE, Michael; FORTANET, Jorge Garcia; KARKI, Rajesh; KATO, Mitsunori; LAMARCHE, Matthew J.; PEREZ, Lawrence Blas; WILLIAMS, Sarah; SENDZIK, Martin; WO2015/107494; (2015); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem